title: Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.
abstract: BACKGROUND
  Profile and correlates of cognitive deficits in first episode (FE) schizophrenia patients are still debated. The present study is aimed to clarify in a large sample of FE patients the extent of impairment in key cognitive domains and its relationships with demographic and clinical variables.
  
  
  METHODS
  The European First Episode Schizophrenia Trial collected demographic, clinical and neurocognitive baseline data in 498 FE patients with minimal or no prior exposure to antipsychotics. Two-hundred-twenty healthy subjects (HS) were also evaluated. Neurocognitive assessment included the Rey Auditory Verbal Learning Test; Trail Making A and B, Purdue Pegboard and Digit-Symbol Coding.
  
  
  RESULTS
  Patients performed worse than HS on all tests (effect sizes from -0.88 to -1.73). Correlations with psychopathological dimensions were weak and involved reality distortion and disorganization. The duration of untreated psychosis (DUP) was not associated with cognitive impairment. Subjects living alone had a better neurocognitive performance, while the occupation status did not reveal any association with cognition.
  
  
  CONCLUSIONS
  A moderate/severe impairment of processing speed, motor dexterity, verbal memory and cognitive flexibility was found in the largest sample of FE patients analyzed so far. The impairment was largely independent from psychopathology and not associated with DUP.
authors.affiliation: Department of Psychiatry, University of Naples SUN, Naples, Italy. sgalderi@tin.it
authors.forename: Silvana
authors.initials: S
authors.lastname: Galderisi
authors.forename: Michael
authors.initials: M
authors.lastname: Davidson
authors.forename: René S
authors.initials: RS
authors.lastname: Kahn
authors.forename: Armida
authors.initials: A
authors.lastname: Mucci
authors.forename: Han
authors.initials: H
authors.lastname: Boter
authors.forename: Mihai D
authors.initials: MD
authors.lastname: Gheorghe
authors.forename: Janusz K
authors.initials: JK
authors.lastname: Rybakowski
authors.forename: Jan
authors.initials: J
authors.lastname: Libiger
authors.forename: Sonia
authors.initials: S
authors.lastname: Dollfus
authors.forename: Juan J
authors.initials: JJ
authors.lastname: López-Ibor
authors.forename: Joseph
authors.initials: J
authors.lastname: Peuskens
authors.forename: Luchezar G
authors.initials: LG
authors.lastname: Hranov
authors.forename: Wolfgang W
authors.initials: WW
authors.lastname: Fleischhacker
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology*; D003431:Cross-Cultural Comparison; D005060:Europe; D005260:Female; D006801:Humans; D007391:International Cooperation; D008297:Male; D015999:Multivariate Analysis; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D012044:Regression Analysis; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013223:Statistics as Topic; D019966:Substance-Related Disorders / Q000150:complications / Q000175:diagnosis; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents